All material subject to strictly enforced copyright laws. © 2022 Managing IP is part of the Euromoney Institutional Investor PLC group.

First compulsory licence application in India

Managing IP Correspondent
September 22, 2011
Share

Indian generic drug maker Natco has filed a compulsory licence application for the patent covering German pharma company Bayer’s anti-cancer drug Nexavar

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

Tags

IndiaNewsPatentsGermanyAsia PacificEuropeEuropeEurope
managing-ip.png
Managing IP Correspondent
Contact

More from across our site

PTABVictoryApjsCOVER.jpg
Five former PTAB judges reveal how to succeed at the board
Lawyers should pay attention to APJs’ questions and remember that PTAB proceedings aren’t jury trials, say former PTAB judges
Rani Mehta, June 30, 2022
GalavaLargeJPEG.jpeg
USPTO cancels first marks under TMA
The USPTO cancelled ‘Galavava’ and 'Surfstar Wake' and partly cancelled ‘Heika’ this month
Rani Mehta, June 30, 2022
Patents
Patent rankings 2022
IP STARS 2022: The full patent rankings
We have published all the 2022 rankings of the leading firms for patent litigation and protection work
Chris Adams, June 30, 2022
Pharmaconcept
UK injunction shift forces pharma to change tack on litigation
In-house and private practice counsel say UK judges have raised the bar for preliminary injunction requests
Rory O’Neill, June 30, 2022
António Campinos wins new EPO term
António Campinos wins new EPO term (but tensions remain)
António Campinos will serve another five years as EPO president – perhaps he’ll calm unrest at the office in that time
Max Walters, June 29, 2022
AdobeStock_277739388.jpg
Firms must go beyond ‘empty’ LGBTQ gestures after pride month
LGBTQ IP lawyers say using rainbow colours and posting solidarity messages on social media must be followed by concrete action
Max Walters, June 29, 2022
Hidden links-comp.jpg
Why brand owners struggle with hidden links
Brand owners bemoan counterfeiters’ latest wheeze and say enforcement authorities should get more involved
Max Walters, June 29, 2022
Covid 19 vaccine
WTO waiver spurs in-house fears of broader deals
Counsel at Bayer, Novartis, a generics company and other firms debate what the WTO’s patent waiver will mean in the short and long term
Rani Mehta, June 29, 2022
Kathi Vidal
Breaking: USPTO releases Section 101 report
The patent office report found that stakeholders were still divided over subject matter eligibility but broadly wanted clarity
Rani Mehta, June 28, 2022
Datamining
UK to expand data mining freedoms for AI
The UKIPO published the results of its consultation on AI and IP today, June 28, and plans to shake up the rules on copyright and data
Rory O’Neill, June 28, 2022
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree